John Bitner, MD
Internal Medicine · Cass City, MINPI 1134118763
Payments from drug & device makers
Across 107 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$371
- Lilly USA, LLC$258
- Mylan Specialty L.p.$234
- GSK$196
- AbbVie$152
- Amgen$113
- plus $563 from 17 others
What the payments were for
- Food & beverage$1,888100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $371 |
| Lilly USA, LLC | 16 | $258 |
| Mylan Specialty L.p. | 12 | $234 |
| GSK | 12 | $196 |
| AbbVie | 7 | $152 |
| Amgen(2 entities) | 6 | $113 |
| Axsome Therapeutics, Inc. | 4 | $93 |
| Exact Sciences | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Novartis | 3 | $49 |
| Pfizer | 3 | $43 |
| Boehringer Ingelheim | 2 | $38 |
| Johnson & Johnson | 2 | $35 |
| Dexcom, Inc. | 2 | $34 |
| Astellas Pharma US Inc | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Merck | 1 | $12 |
How this compares
$1,888 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 191 | $211,064 |
| JardianceEmpagliflozin | 155 | $135,144 |
| OzempicSemaglutide | 98 | $131,232 |
| MounjaroTirzepatide | 74 | $95,797 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $55,389 |
| TrulicityDulaglutide | 29 | $45,444 |
| XareltoRivaroxaban | 40 | $32,703 |
| JanuviaSitagliptin Phosphate | 21 | $31,725 |
| VraylarCariprazine Hcl | 13 | $18,975 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $18,662 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $13,254 |
| FarxigaDapagliflozin Propanediol | 16 | $12,873 |
| MyrbetriqMirabegron | 16 | $11,340 |
| Spiriva RespimatTiotropium Bromide | 23 | $11,084 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $8,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $43 | $211,064191 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $38 | $151,520189 claims |
| Lilly USA, LLCMounjaro, Trulicity | $258 | $141,240103 claims |
| Novo NordiskOzempic | $371 | $131,23298 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $196 | $82,539108 claims |
| Johnson & JohnsonXarelto | $35 | $32,70340 claims |
| MerckJanuvia | $12 | $31,72521 claims |
| AbbVieVraylar | $152 | $18,97513 claims |
| AstraZenecaFarxiga | $16 | $12,87316 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $11,34016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Cass City
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.